Goldman Sachs Starts ArriVent BioPharma (AVBP) at Buy, 'Differentiated and de-risked across select lung cancer populations'
Tweet Send to a Friend
(Updated - February 20, 2024 3:48 AM EST)
Goldman Sachs analyst Corinne Johnson initiates coverage on ArriVent BioPharma (NASDAQ ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Goldman Sachs analyst Corinne Johnson initiates coverage on ArriVent BioPharma (NASDAQ ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
